Use of nMoABs for the Treatment of COVID-19 in Patients With HM.

Inclusion Criteria: * All patients must meet all the following criteria for study entry: 1. Age equal to or greater than 18 years of age. 2. Diagnosis of HM (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status. 3. Third generation rapid molecular or antigen test positive for SARS-CoV-2 from February 2020 until May 2021 4. Treatment with anti SARS CoV 2 nMoAbs approved by AIFA 5. Not hospitalized for COVID-19 at the time of nMoAbs administration 6. Not on oxygen therapy at the time of nMoAbs administration 7. At least one of the following symptoms for no more than 10 days: * Fever * Cough * Anosmia * Ageusia / dysgeusia * Pharyngodynia * Asthenia * Headache * Nausea * Diarrhea * Myalgia * Dyspnea * Tachypnea 8. Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable). Exclusion Criteria: * 1\. Hematological diseases, other than HM. 2\. Not tested positive for SARS-CoV-2 3\. Patients in disease remission "off therapy" for more than 6 months 4\. Immune plasma treatment in the previous two months